BAY 361677
Alternative Names: Interleukin-4 variant - BayerLatest Information Update: 06 Oct 2006
At a glance
- Originator Bayer
- Class Antineoplastics
- Mechanism of Action Apoptosis stimulants; Interleukin 4 receptor agonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Multiple sclerosis; Precursor cell lymphoblastic leukaemia-lymphoma